PMA device
SIR-Spheres Y-90 resin microspheres
Sirtex Medical, Inc. · Microspheres Radionuclide (NAW, Class III) · First FDA decision Jul 1, 2025, newest Jul 1, 2025Liver disease and liver cancer
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
18
Naming "SIR-Spheres Y-90 resin"
MAUDE reports
2
Brand "SIR-Spheres Y-90 resin", since 2015
PubMed studies
5
Mentioning "SIR-Spheres Y-90 resin"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing SIR-Spheres Y-90 resin microspheres
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- SIR-Spheres Y-90 resin microspheresPMA supplement
P990065-S014 · Decided Jul 1, 2025 · 532 days after receipt · Panel Track
Device type: Microspheres radionuclide (NAW) · Radiology & Imaging
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "SIR-Spheres Y-90 resin", any status and sponsor, newest update first.
- SIRT With Tremelimumab and Durvalumab for Resectable HCCActive, not recruiting
Jiping Wang, MD, PhDAcademic, hospital or other
NCT05701488 · 20 participants · Start Apr 21, 2023 · Primary completion Oct 1, 2027
Device: SIRT · For: Resectable Hepatocellular Carcinoma; Hepatocellular Carcinoma; Hepatocellular Cancer
Sites: Los Angeles, California; Boston, Massachusetts · 3 sites in all
17 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "SIR-Spheres Y-90 resin", and for the whole product code for context.
This brand
2 reports: 1 malfunction, 1 injury, 0 death
Whole product code NAW
540 reports: 29 malfunction, 349 injury, 126 death
Newest reports for this brand
SIRTEX TECHNOLOGY PTY LTD / SIRTEX MEDICAL LIMITED
3005579300-2018-00006 · Received Aug 16, 2018 · Event dated Jul 22, 2018
Device type: Microspheres Radionuclide (NAW)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Fever; Unspecified Infection; Vomiting
1 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "SIR-Spheres Y-90 resin"[tiab]. The summary above synthesizes these.
- Recommendations for SIR-Spheres Y-90 resin microspheres in chemotherapy-refractory/intolerant colorectal liver metastases.
Aranda E, Aparicio J, Bilbao JI, et al. · Future Oncol · 2017Review
- The SIRveNIB and SARAH trials and the role of SIR-Spheres® Y-90 resin microspheres in the management of hepatocellular carcinoma.
Chow PK, Gandhi M, Gebski V · Future Oncol · 2017Editorial
- A cost-utility analysis of SIR-Spheres Y-90 resin microspheres versus best supportive care in the treatment of unresectable metastatic colorectal cancer refractory to chemotherapy in the UK.
Brennan VK, Colaone F, Shergill S, et al. · J Med Econ · 2020
- Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life.
Agirrezabal I, Brennan VK, Colaone F, et al. · Adv Ther · 2022Research Support, Non-U.S. Gov't
- A cost analysis of SIR-Spheres yttrium-90 resin microspheres versus tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma in France, Italy, Spain and the UK.
Pollock RF, Colaone F, Guardiola L, et al. · J Med Econ · 2020
Other devices of this type
Also filed under product code NAW.
- TheraSphereBoston Scientific Corporation · PMA 2026
- SIR-Spheres microspheresSirtex Medical, Inc. · PMA 2017
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.